Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1662579 · FYE Dec 31 · Prices AT CLOSE 2026-08-19 (USD) Last $4.21 · Day +0.72% · Mkt cap $514M · 1Y +52.5% · Off 52W high −18.6% · Vol (1Y) 90.2% Price2023-08-21 → 2026-08-19 CCCC close: $3.3 on 2023-08-21 to $4.2 on 2026-08-19. Split-adj closes · 240 of 1,377 · price returnⓘ At a glance | Short interest24.7% of sh out | | Days to cover11.1d | | 13F net flow (QoQ)+0.74% | | Top-10 13F concentration59.6% | | Next report (est.)2026-11-10 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Sales (TTM)$35.0M | | Earnings (TTM)-$101.4M | | ROE−44.4% | | Net margin−292.1% | | ROIC−53.2% | | Sales growth 3Y5.0% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD+120.4% | | 1Y+52.5% | | 3Y+29.1% | | 5Y−89.7% | | Since incept. (ann.)−34.1% |
Total return · from 2021-02-22ⓘ Risk | Ann. volatility (1Y)90.2% | | Ann. volatility (3Y)134.7% | | Sharpe (1Y)0.86 | | Sharpe (3Y)0.58 | | Max drawdown (1Y)−52.1% | | Max drawdown (3Y)−90.0% | | Beta (3Y vs SPY)4.01 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| MORGAN STANLEY | 9.1M | $24M | 9.30% | +1.0% | | RA CAPITAL MANAGEMENT, L.P. | 8.0M | $21M | 8.20% | +0.0% | | Bain Capital Life Sciences Investors, LLC | 7.2M | $19M | 7.35% | +0.0% | | Lynx1 Capital Management LP | 7.0M | $18M | 7.17% | −1.4% | | VANGUARD CAPITAL MANAGEMENT LLC | 3.9M | $10M | 3.96% | new | | Soleus Capital Management, L.P. | 3.8M | $10M | 3.90% | +0.0% | | TWO SIGMA INVESTMENTS, LP | 3.0M | $8M | 3.11% | +101.1% | | WASATCH ADVISORS LP | 3.0M | $8M | 3.04% | −31.8% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-11 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-11 | −$0.18 | — | $6.6M | +2.8% | | 2026-03-31 | 2026-05-12 | −$0.20 | — | $6.2M | −15.0% | | 2025-12-31 | 2026-02-26 | — | — | $11.0M | +112.8% | | 2025-09-30 | 2025-11-06 | −$0.44 | — | $11.2M | −26.9% |
As-reported XBRL · next 2026-11-10 est.ⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
|
